Liquidia (NASDAQ:LQDA) Insider Scott Moomaw Sells 18,314 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 18,314 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $36.79, for a total transaction of $673,772.06. Following the transaction, the insider owned 187,640 shares in the company, valued at approximately $6,903,275.60. The trade was a 8.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Scott Moomaw also recently made the following trade(s):

• On Monday, January 12th, Scott Moomaw sold 20,533 shares of Liquidia stock. The shares were sold at an average price of $37.43, for a total transaction of $768,550.19.

Liquidia Price Performance

Shares of LQDA opened at $36.61 on Thursday. The company has a 50 day moving average price of $37.74 and a 200-day moving average price of $31.73. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $46.67. The stock has a market capitalization of $3.23 billion, a PE ratio of -44.11 and a beta of 0.52. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm’s quarterly revenue was up 3072.4% on a year-over-year basis. Equities analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Institutional Trading of Liquidia

A number of institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP purchased a new position in Liquidia during the 4th quarter worth $3,148,000. Invesco Ltd. raised its stake in Liquidia by 428.3% in the fourth quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after buying an additional 341,009 shares during the last quarter. XTX Topco Ltd acquired a new stake in Liquidia in the fourth quarter worth about $1,214,000. nVerses Capital LLC purchased a new stake in shares of Liquidia during the fourth quarter worth about $335,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of Liquidia during the fourth quarter worth about $3,107,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on LQDA shares. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. Wells Fargo & Company upped their price objective on Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Monday. HC Wainwright lifted their target price on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Finally, Needham & Company LLC boosted their target price on shares of Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).